Huntington’s Disease Clinical Trials Update: September 2024
In this edition of the Huntington's Disease Clinical Trials Update, we expand on the ongoing extension study of PTC518 from PTC Therapeutics, including 12-month interim results from the parent study. We also discuss 24-month interim results from uniQure's AMT-130 program and 28-week follow-up results from Wave Life Sciences' SELECT-HD clinical trial of WVE-003. Additionally, we provide a comprehensive listing of all currently registered and ongoing clinical trials in Huntington's disease.
Authors
- Edward J. Wild (ORCID: https://orcid.org/0000-0002-6921-7887)
- Sarah J. Tabrizi (ORCID: https://orcid.org/0000-0003-2716-2045)
- Mena S. Farag (ORCID: https://orcid.org/0000-0002-0679-0117)
Institutions
- Huntington's Disease Association (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Journal of Huntington s Disease
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1177/18796397241293955
- Citations
- 13
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.49